CN109395063A - Application of the G-CSF in treatment ITP patient's dysimmunity - Google Patents
Application of the G-CSF in treatment ITP patient's dysimmunity Download PDFInfo
- Publication number
- CN109395063A CN109395063A CN201811591053.XA CN201811591053A CN109395063A CN 109395063 A CN109395063 A CN 109395063A CN 201811591053 A CN201811591053 A CN 201811591053A CN 109395063 A CN109395063 A CN 109395063A
- Authority
- CN
- China
- Prior art keywords
- csf
- ratio
- ifn
- gata
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000028622 Immune thrombocytopenia Diseases 0.000 title claims abstract description 43
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 title claims abstract description 43
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title claims abstract description 40
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title claims abstract description 40
- 238000011282 treatment Methods 0.000 title claims description 11
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 title 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims abstract description 42
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 claims abstract description 42
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims abstract description 20
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims abstract description 20
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 20
- 210000000447 Th1 cell Anatomy 0.000 claims abstract description 10
- 210000004241 Th2 cell Anatomy 0.000 claims abstract description 10
- 231100000673 dose–response relationship Toxicity 0.000 claims abstract description 3
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 claims abstract 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 abstract description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000012404 In vitro experiment Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 102000004388 Interleukin-4 Human genes 0.000 description 30
- 108090000978 Interleukin-4 Proteins 0.000 description 30
- 102100037850 Interferon gamma Human genes 0.000 description 28
- 108010074328 Interferon-gamma Proteins 0.000 description 28
- 102000003816 Interleukin-13 Human genes 0.000 description 26
- 108090000176 Interleukin-13 Proteins 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- -1 IL-2 Proteins 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本药涉及一种药物新用途，具体涉及粒细胞集落刺激因子调节原发免疫性血小板减少症患者PBMCs的Th1/Th2细胞比率治疗原发免疫性血小板减少症。体外实验证明细胞集落刺激因子可以以剂量依赖性的方式降低原发免疫性血小板减少症患者的Th1/Th2比率，T‑bet/GATA‑3的比率降低证明细胞集落刺激因子可通过间接的方式降低Th1/Th2比率，该研究首次显示细胞集落刺激因子对原发免疫性血小板减少症患者的潜在治疗作用。
The drug relates to a new drug use, specifically involving granulocyte colony-stimulating factor regulating the Th1/Th2 cell ratio of PBMCs of patients with primary immune thrombocytopenia to treat primary immune thrombocytopenia. In vitro experiments demonstrate that CSF can reduce Th1/Th2 ratio and T-bet/GATA-3 ratio in a dose-dependent manner in patients with primary immune thrombocytopenia Th1/Th2 ratio, this study shows for the first time the potential therapeutic effect of colony-stimulating factor in patients with primary immune thrombocytopenia.
Description
Technical field
The present invention relates to the treatments of essential thrombocytopenia, and specifically G-CSF is in treatment ITP Patients Patients
It is applied in dysimmunity.
Background technique
Primary immune thrombocytopenia (ITP) is the autoimmune reduced by blood platelet, with the characteristics of dermatorrhagia
Disease, with complicated Pathologic Characteristics.Macrophage, CD8+T cell, autoantibody can destroy blood platelet, in the hair of ITP
It plays an important role during disease.However helper T lymphocyte (Th) plays important on-off action in the generation of mediate B cell antibody.
In addition, it is the autoimmunity disease mainly showed that ITP, which is with Th1 polarization, the degree that Th1/Th2 ratio increases and platelet count and disease
Sick severity is negatively correlated.Therefore reverse Th1 polarization, restore Th1/Th2 balance may be risen in the treatment of ITP patient it is latent
Important function.
Th cell is played regulatory role in immune system by secrete cytokines.Th1 and Th2 cell is being immunoreacted
Effect it is different.Wherein, Th1 cell Major Secretory cytokines interferon (IFN)-γ and interleukin (IL) -2, in immune disease
It plays an important role in the pathogenic process of disease；And Th2 cell Major Secretory cell factor IL-4 and IL-13, in autoimmune disease
Pathogenic process in shield.In addition, some factors have been demonstrated that the secretion of Th1 and Th2 cell factor, example can be influenced
Such as: regulatory T cells, granulocyte colony stimulating factor (G-CSF), T box (T-bet) and GATA combination egg in T lymphocyte
White 3 (GATA-3).In addition, T-bet and GATA-3 are two important T cell transduced elements, be adjusted Th1 and Th2 cell because
Subbase because expression, T cell differentiation in play an important role.T-bet/GATA-3 is believed to really react Th1/Th2
State.
G-CSF is an important Hemopoietic factor of medullary system, while being the necessary mediation person of immune response again, and connection is inherently exempted from
Epidemic disease reaction and the acquired immune response play an important role in inducing and maintaining T cell tolerance.In health donors, G-CSF can
To reduce cell factor IFN-γ, the generation of IL-4 is improved, reduces Th1/Th2 ratio.Delay and/or treat in addition, G-CSF has
The effect of autoimmunity disease.However, effect of the G-CSF in the dysimmunity of ITP is still unclear.
We assume that G-CSF can reduce the Th1/Th2 ratio that ITP patient increases extremely, in order to confirm this it is assumed that I
Study effect of the G-CSF in ITP patient's Th1/Th2 ratio, our result show that G-CSF change ITP patient Th1/
The potential treatment of Th2 ratio acts on, and illustrates G-CSF in the indirect adjustment mechanism of Th1/Th2 cell.
Summary of the invention
The invention discloses application of the G-CSF in treatment ITP patient's dysimmunity, and G-CSF is by adjusting patient Th1/
The ratio of Th2 realizes the treatment to primary immune thrombocytopenia.
G-CSF can reduce Th1/Th2 cells ratio by reducing T-bet/GATA-3 ratio indirectly.
The present invention provides a kind of potential effective therapeutic agent, cell collection for primary immune thrombocytopenia patient
G-CSF can reduce the Th1/Th2 ratio of primary immune thrombocytopenia patient in a manner of dose-dependent,
The ratio of T-bet/GATA-3, which reduces, proves that colony-stimulating factor can reduce Th1/Th2 ratio by indirect mode, this
Application shows that colony-stimulating factor acts on the potential treatment of primary immune thrombocytopenia patient for the first time.
Detailed description of the invention
Fig. 1 be G-CSF to the cytokine release of ITP patient (n=12) and normal healthy controls person (n=12) PBMCs and
The effect of Th1/Th2 cytokine-expressing ratio.After various concentration G-CSF acts on PBMCs for 24 hours, PHA (10ug/mL) training is added
Support 48h.The expression of IFN-γ (A), IL-2 (B), IL-4 (C) and IL-13 (D) in cell culture fluid is detected by ELISA method
Amount.ITP patient (E) and normal healthy controls person (F) Th1 (IFN-γ and IL-2) and Th2 (IL-4 and IL-13) ratio.Data use
The form of mean ± standard deviation is expressed.
Fig. 2 be G-CSF to the IFN-γ of ITP patient (n=12) and normal healthy controls person (n=12) PBMCs, IL-2, IL-4,
After the effect various concentration G-CSF of IL-13, T-bet and GATA-3mRNA expression acts on PBMCs for 24 hours, PHA culture is added
48h.RT-PCR detects the IFN-γ (A) of PBMCs, IL-2 (B), IL-4 (C), IL-13 (D), T-bet (E) and GATA-3's (F)
MRNA expression.Calculate ITP patient and normal healthy controls person's IFN-γ/IL-4 (G), IL-2/IL-13 (H) and T-bet/GATA-
3 (I) ratios.Data are expressed in the form of mean ± standard deviation.
Specific embodiment
The present invention takes human peripheral blood mononuclear cell (PBMCs) to cultivate, and G-CDF is then added and is cultivated, after
Phase stimulates through PHA, sample to be tested is made in trizol solution effects, is then detected.
Detection specifically includes that
The PBMCs of ELISA detection in vitro culture is secreted into cell factor (IFN-γ, IL-2, IL-4, IL- in supernatant
13) expression.
RT-PCR detect in vitro culture PBMCs based intracellular cvtokine (IFN-γ, IL-2, IL-4, IL-13) and T-bet,
The expression of the mRNA of GATA-3 and β-actin.
Embodiment
Research object includes 12 patients with chronic idiopathic thrombocytopenlc purpura and the normal healthy controls person that 12 ages, genders are consistent.Chronic ITP
The main diagnostic criteria according to the publication of the world ITP working group in 2009 of diagnosis, while excluding the relevant other diseases of ITP and suffering from
Person.Patient does not receive hormone therapy.Male 5, female 7, the median age 49.5 years old (17~79 years old), blood platelet median 10.0
×109/ L (0.4~19.6 × 109/L).In 12 patients of this research, 5 (41.7%) example patient antiplatelet antibodies are positive.
Table 1 shows the clinical characters of ITP patient.
In table 1, M indicates that gender is male；F indicates that gender is female.
The operation that the studies above object is followed the steps below:
1, the separation of PBMCs, culture and the anticoagulant peripheral blood 5ml of experiment process taking heparin sodium, by 1500g at room temperature from
15 minutes acquisition blood plasma of the heart needs to melt in 37 DEG C of water-baths when -80 DEG C of storages, blood plasma use.Pass through lymphocyte point
Cell concentration after giving cell count, is adjusted to 1 × 10 by chaotropic PBMCs6/ ml is placed in 1640 culture medium of RPMI and (contains
10%FCS) cultivate, while be added various concentration G-CSF (0ng/ml, 12.5ng/ml, 25ng/ml, 50ng/ml, 100ng/ml,
Xiamen Amoytop Biotech Co., Ltd.), 10ug/ml PHA is added in 5%CO2 incubator, after 24 hours to stimulate
Secrete cytokines.By centrifugation after being co-cultured 72 hours under the conditions of 37 DEG C, supernatant is taken, is placed in the centrifuge tube newly prepared, -80
It is frozen in DEG C refrigerator spare；1ml trizol solution is added in PBMCs, gently blows and beats cell precipitation with suction pipe, it is complete to cell
After dissolution, frozen in -80 DEG C of refrigerators spare.
2, ELISA detects cell factor
ELISA kit detects cell factor IFN-γ, IL-2, IL-4, IL-13 after blood plasma G-CSF and PBMCs culture
Variation, each experiment are repeated twice.Without significant cross reaction between different recombinant cytokines.Detecting the minimum rate of accumulation is respectively
39.1pg/mL (G-CSF), 0.99pg/mL (IFN-γ), 9.2pg/Ml (IL-2), 1.3pg/mL (IL-4), 0.7pg/ml (IL-
13)。
3, IFN-γ in RT-PCR method detection PBMCs, IL-2, IL-4, the transcription of IL-13, T-bet and GATA-3
After G-CSF is handled 72 hours, total serum IgE is extracted from 1 × 106PBMCs using TRIzol, passes through ImProm-IITMIt is inverse
The temperature that transcriptase reverse transcription 500ng RNA. is used is: 20 DEG C of 5min, 42 DEG C of 30min, 70 DEG C of 15min, 4 DEG C of maintenances.cDNA
Be stored in -20 DEG C it is spare.The loop parameter setting of PCR reaction: 95 DEG C, 95 DEG C of 15s, 60 DEG C of 30s, 72 DEG C of 30s, connect after ten minutes
Continuous 40 circulations.All reactions are in triplicate.
Pass through 2-ΔΔCtMethod calculates target gene (IFN-γ, IL-2, IL-4, IL-13, T-bet and GATA-3) and pipe
The opposite variation that family's gene (β-actin) is expressed.Wherein β-actin, IFN-γ, IL-2, IL-4, IL-13, T-bet and GATA-
3 primers sequence such as table 2:
Above-mentioned testing result and data are analyzed and summarized:
Effect of the 1.G-CSF to Th1 and Th2 cell cytokine secretion
Under PHA effect, G-CSF and the PBMCs co-incubation of various concentration detect PBMCs secretion by ELISA method
Cell factor amount, comprising: IFN-γ, IL-2, IL-4 and IL-13.Such as Figure 1A and B, when no G-CSF is handled, ITP patient IFN-
The expression of γ and IL-2 is significantly higher than normal healthy controls person (IFN-γ, P < 0.001；IL-2, P < 0.001), and IL-4 (figure C)
And IL-13 (figure D) expression is lower than normal healthy controls person (IL-4, P < 0.01；IL-13, P < 0.001).G-CSF is with dose-dependant
Property mode reduce ITP patient and normal healthy controls person Th1 (IFN-γ+IL-2)/Th2 (IL-4+IL-13) ratio (figure E and
F)；And IFN-γ and IL-2 are gradually decreased, IL-4 and IL-13 are gradually increased.In ITP patient, 100ng/mL there are the case where
Under, IFN-γ and IL-2 reduce by 34.0% ± 1.2% (P < 0.05) and 22.4% ± 3.5% (P < 0.05) respectively；IL-4 and IL-
13 are respectively increased 111.7% ± 75.8% (P < 0.05) and 66.9% ± 17.5% (P < 0.05).Finally, Th1 (IFN-γ+IL-
2) ratio of/Th2 (IL-4+IL-13) reduces by 58.9% ± 2.8% (P < 0.05).In normal healthy controls person, in 100ng/mLG-
In the presence of CSF, IFN-γ and IL-2 reduce respectively 43.0% ± 6.7% (P < 0.05) and 27.9% ± 7.0% (P <
0.05)；39.9% ± 17.2% (P < 0.05) and 18.0% ± 5.6% (P < 0.05) is respectively increased in IL-4 and IL-13.Finally,
The ratio of Th1 (IFN-γ+IL-2)/Th2 (IL-4+IL-13) reduces by 44.6% ± 6.5% (P < 0.05).
Blood plasma G-CSF concentration is lower than the minimum detection value of ELISA kit.
2, G-CSF is to IFN-γ on PBMCs, IL-2, IL-4, the expressional function of the mRNA of IL-13, T-bet and GATA-3
Analysis
As shown in Fig. 2, under various concentration G-CSF effect, we by the RT-PCR detection IFN-γ of PBMCs, IL-2,
The expression of the mRNA of IL-4, IL-13, T-bet and GATA-3.When no G-CSF is acted on, IFN-γ/IL-4, IL-2/ of ITP patient
The expression ratio of IL-13 and T-bet/GATA-3 4.23 times higher than the expression ratio of normal healthy controls person, 3.97 times and 3.26 respectively
Again (P < 0.05).With increasing for G-CSF concentration, in ITP patient and normal healthy controls person, IFN-γ, IL-2 and T-bet
The expression of mRNA reduces；The expression of the mRNA of IL-4, IL-13 and GATA-3 are increased；IFN-γ/IL-4, IL-2/IL-13 and T-
The expression ratio of bet/GATA-3 reduces.In 100ng/mL G-CSF effect, IFN-γ, IL-2 and the T- of ITP Patient cells
The expression of the mRNA of bet reduce by 38.9% ± 13.8%, 30.9% ± 9.8% and 22.1% ± 7.1% respectively (P <
0.05)；The expression of these mRNA of normal healthy controls person reduces by 27.7% ± 2.5%, 24.7% ± 5.5% He respectively
15.8% ± 5.5% (P < 0.05).In addition, the expression of the mRNA of IL-4, IL-13, GATA-3 of ITP Patient cells are distinguished
Improve 54.4% ± 12.2%, 26.7% ± 9.5% and 70.2% ± 24.8% (P < 0.05)；These mRNA of normal healthy controls person
Expression 46.7% ± 17.5%, 24.0% ± 9.2% and 31.7% ± 11.4% (P < 0.05) is respectively increased.Finally,
ITP patient's IFN-γ/IL-4, IL-2/IL-13 and T-bet/GATA-3 ratio reduces by 60.4% ± 13.7%, 45.5% respectively
± 8.2% and 53.3% ± 9.8% (P < 0.05), these ratios of normal healthy controls person reduce by 50.7% ± 5.3% respectively,
39.5% ± 10.2% and 35.5% ± 8.7% (P < 0.05).
The experiment confirms that G-CSF can be in the Th1/Th2 cell for reducing ITP patient in a manner of relying property of dose-dependant in vitro
Ratio.T-bet/GATA ratio, which reduces, confirms that G-CSF has indirect immune regulation mechanism to Th1/Th2.Evidence is bright at present, G-
CSF has potential therapeutic effect to ITP patient.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811591053.XA CN109395063A (en) | 2018-12-22 | 2018-12-22 | Application of the G-CSF in treatment ITP patient's dysimmunity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811591053.XA CN109395063A (en) | 2018-12-22 | 2018-12-22 | Application of the G-CSF in treatment ITP patient's dysimmunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109395063A true CN109395063A (en) | 2019-03-01 |
Family
ID=65461322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811591053.XA Pending CN109395063A (en) | 2018-12-22 | 2018-12-22 | Application of the G-CSF in treatment ITP patient's dysimmunity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109395063A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113156141A (en) * | 2021-03-23 | 2021-07-23 | 复旦大学附属中山医院 | Multi-cytokine detection chip and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| CN1756561A (en) * | 2002-12-31 | 2006-04-05 | 免疫医疗公司 | Methods of immunization of B-cell malignancies and autoimmune diseases by use of non-conjugated and conjugated antibodies, antibody combinations and fusion proteins |
-
2018
- 2018-12-22 CN CN201811591053.XA patent/CN109395063A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| CN1756561A (en) * | 2002-12-31 | 2006-04-05 | 免疫医疗公司 | Methods of immunization of B-cell malignancies and autoimmune diseases by use of non-conjugated and conjugated antibodies, antibody combinations and fusion proteins |
Non-Patent Citations (2)
| Title |
|---|
| FEI GE等: "Granulocyte colony-stimulating factor decreases the Th1/Th2 ratio in peripheral blood mononuclear cells from patients with chronic immune thrombocytopenic purpura in vitro", 《THROMBOSIS RESEARCH》 * |
| 黄玉等: "成人难治及复发ITP的个体化治疗及研究进展", 《中国实验血液学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113156141A (en) * | 2021-03-23 | 2021-07-23 | 复旦大学附属中山医院 | Multi-cytokine detection chip and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koch et al. | Th9 and other IL-9-producing cells in allergic asthma | |
| Kato | Group 2 innate lymphoid cells in airway diseases | |
| Whitehead et al. | IL-35 production by inducible costimulator (ICOS)–positive regulatory T cells reverses established IL-17–dependent allergic airways disease | |
| Vojdani et al. | Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL-2 and IL-15 | |
| Mills | Induction, function and regulation of IL‐17‐producing T cells | |
| van Hamburg et al. | TNF blockade requires 1, 25 (OH) 2D3 to control human Th17-mediated synovial inflammation | |
| Mu et al. | Mesenchymal stem cells moderate experimental autoimmune uveitis by dynamic regulating Th17 and Breg cells response | |
| Wang et al. | Updated insight into the role of Th2-associated immunity in systemic lupus erythematosus | |
| Wang et al. | Dimethyl itaconate inhibits antigen‐specific Th17 cell responses and autoimmune inflammation via modulating NRF2/STAT3 signaling | |
| CN109395063A (en) | Application of the G-CSF in treatment ITP patient's dysimmunity | |
| Woods et al. | Low-level production of interleukin-13 in synovial fluid and tissue from patients with arthritis | |
| Veenbergen et al. | The natural soluble form of IL-18 receptor β exacerbates collagen-induced arthritis via modulation of T-cell immune responses | |
| Guo et al. | IL-23, rather than IL-17, is crucial for the development of ovalbumin-induced allergic rhinitis | |
| CN114191544A (en) | Application of deubiquitinase in the preparation of drugs for preventing or treating acute graft-versus-host disease and graft-versus-leukemia | |
| JP2015063550A (en) | Composition for treating intestinal inflammatory disease | |
| Liang et al. | Effect of blocking the OX40/OX40L signaling pathway by siRNA interference on animal experimental study of allergic rhinitis | |
| Kokkas et al. | The role of cytokines in pulp inflammation | |
| US20230018682A1 (en) | Methods and compositions of natural killer cell adoptive transfer therapy | |
| Li et al. | Interleukin-28A promotes IFN-γ production by peripheral blood mononuclear cells from patients with Behçet’s disease | |
| Choi et al. | IL-2/IL-2 antibody immune complex regulates HSV-induced inflammation through induction of IL-2 receptor alpha, beta, and gamma in a mouse model | |
| RU2416799C1 (en) | Method for prediction of efficacy of infliximab inclusion in therapy of patients with rheumatoid arthritis | |
| Takeuchi et al. | Possibility of inducing anterior chamber-associated immune deviation by TGF-β2 treatment of monocytes isolated from Behcet's patients | |
| Whitehead et al. | IL-35 production by ICOS+ tregs reverses established IL-17-dependent allergic airways disease | |
| Mohammed et al. | Evaluation of interleukin 17 A level and lipid profile in diabetic female patients treated by Metformin and Glimepiride in Kirkuk City Iraq | |
| Al-Ameri et al. | Study of Tumor Necrosis Factor-β (Lymphotoxin) and Cell Death Receptor (TNFR-2) in Rhumatiod Arthritis with Type 2 Diabetes Mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190301 |
|
| WD01 | Invention patent application deemed withdrawn after publication |